Drug Profile

FLT 190

Alternative Names: FLT190 AAV gene therapy; FT-190

Latest Information Update: 20 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University College London
Developer Spur Therapeutics
Class Gene therapies
Mechanism of Action Alpha-galactosidase replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Fabry's disease
New Molecular Entity No

Highest Development Phases

Suspended Fabry's disease

Most Recent Events

17 Jun 2024 Freeline Therapeutics is now called as Spur Therapeutics
20 Feb 2024 Freeline Therapeutics has been acquired by Syncona
28 Sep 2023 Freeline Therapeutics completes the phase II MARVEL 2 trial in Fabry's disease in Austria, Germany and United Kingdom (SC) (EudraCT2019-004645-32) (NCT04455230)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com